DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells-Reference-Cited by-同舟云学术

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

Published:2018-03-02 Issue:8 Volume:118 Page:1062-1073
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bruyer Angelique,Maes Ken,Herviou Laurie,Kassambara Alboukadel,Seckinger Anja,Cartron Guillaume,Rème Thierry,Robert Nicolas,Requirand Guilhem,Boireau Stéphanie,Müller-Tidow Carsten,Veyrune Jean-luc,Vincent Laure,Bouhya Salahedine,Goldschmidt Hartmut,Vanderkerken Karin,Hose Dirk,Klein Bernard,De Bruyne Elke,Moreaux Jerome

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0025-x.pdf

Reference73 articles.

1. Heuck, C. J. et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J. Immunol. 190, 2966–2975 (2013).

2. Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553–562 (2010).

3. Hollenbach, P. W. et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5, e9001 (2010).

4. Maes, K. et al. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers 5, 430–461 (2013).

5. Feng, R. et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol. Cancer Ther. 7, 1494–1505 (2008).

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer;Cell Death Discovery;2024-03-15

2. HDAC7: a promising target in cancer;Frontiers in Oncology;2024-02-28

3. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine;Cell Death Discovery;2024-01-15

4. Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase;Blood Advances;2023-03-20

5. Dynamic Regulation of DNA Methylation and Brain Functions;Biology;2023-01-18